Bonner Michael 4
4 · CUMBERLAND PHARMACEUTICALS INC · Filed Jun 11, 2021
Insider Transaction Report
Form 4
Bonner Michael
Chief Financial Officer
Transactions
- Award
Options (right to buy)
2021-03-17+5,000→ 5,000 totalExercise: $3.22From: 2025-03-17Exp: 2031-03-17→ Common Stock (5,000 underlying) - Tax Payment
Common Stock
2021-03-17$3.22/sh−1,067$3,436→ 19,220 total - Other
Common Stock
2021-05-17$2.83/sh−7,500$21,225→ 11,720 total - Disposition to Issuer
Options (right to buy)
2021-05-17−5,000→ 0 totalExercise: $3.22From: 2025-03-17Exp: 2031-03-17→ Common Stock (5,000 underlying)
Footnotes (3)
- [F1]This transaction represents shares purchased by the Company to cover the tax withholding obligations for the vesting of shares.
- [F2]Resigned position as Chief Financial Officer effective May 17, 2021. All unvested equity awards forfeited upon resignation.
- [F3]100% vesting on March 17, 2025.